SEC Form 4 · accession 0001214659-26-007677
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julie Krop
Director
Period of report
Jun 23, 2026
Accepted (ET)
Jun 24, 2026 · 11:11 am EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001398733
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 23, 2026 | M | 25,000 | $0.7132 | A | 25,000 | D | |
| Common Stock | Jun 23, 2026 | S | 25,000 | $5.0157 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $0.7132 | Jun 23, 2026 | M | 25,000 | D | — | Jun 22, 2032 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
- F2The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
- F3This option was granted on June 22, 2022 and is fully vested.